In summary, using an integrated discovery platform that included defined cell lines, a genetic mouse model of aggressive disease and clinically annotated human samples, we identified downregulation of miR34b and reciprocal increased levels of Sox2 as a biomarker of progressing prostate cancer while still at an androgen-dependent stage. The gene discussed is SOX2; the disease is prostate cancer.